Type:
Educational Exhibit
Keywords:
Not applicable, Retrospective, Metastases, Cancer, Comparative studies, CT-High Resolution, Oncology, Lung, Oncologic Imaging, Performed at one institution
Authors:
V. Brazão De Carvalho1, J. M. Veiga2, S. Alfarroba2, C. A. S. Ruano1, A. Araújo1; 1Lisbon/PT, 2Lisboa/PT
DOI:
10.26044/ecr2020/C-08648
Background
Lung adenocarcinomas are characterized by distinct genomic changes that allow further classification into clinically relevant molecular subsets, qualifying them as important molecular target in cancer therapy. Specifically, the discovery of epidermal growth factor receptor (EGFR) mutations is associated with a dramatic clinical response to the EGFR tyrosine kinase inhibitors (EGFR TKIs) - erlotinib, gefitinib, afatinib and osimertinib.
Clinically this type of mutation is associated with non-smoking status, female gender and East Asian ethnicity3.
Computed tomography (CT) imaging features in EGFR mutated adenocarcinomas may help identify patients who may benefit from expedited molecular testing, even in unexpectedly negative genotyping, or provide a better selection of the most suspicious tumor if multiple tumors are present in same patient.